The analysis of factor involved in decreased HBsAg in HBV patients treated with nucleos(t)ide analogue
Not Applicable
Recruiting
- Conditions
- Chronic hepatitis B virus infected patient
- Registration Number
- JPRN-UMIN000029439
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with difficult to manage cardiac disease 2. Patients who have a history of allergic reaction by nucleos(t)ide analogues 3. Patients treated with contraindicated drug together with nucleos(t)ide analogues 4. Patients by whom doctor in charge has determined to be inappropriate as a subject 5. Patients by whom principal investigator has determined to be inappropriate as a subject
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The degree of HBV-DNA and HBsAg decline 1 year after administration of nucleos(t)ide analugues
- Secondary Outcome Measures
Name Time Method 1. The degree of HBV-DNA and HBsAg decline 3, 5, 10 years after administration of nucleos(t)ide analugues 2. Relevalence between IL28B SNPs and HBsAg decline 3. Relevalence between serum IFN-lambda3 and HBsAg decline 4. Relevalence between emergence of resistant associated variant and antiviral effect 5. efficacy of improvement of hepatic fibrosis 6. efficacy of improvement of AST/ALT